GlassScriptPhysician profile
Sarah E Johnson
NPI 1881027373
$4,464.28
in general payments reported to CMS, 2019-2025
38 companies · $76.66 in 2025
The $76.66 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,752 · 2022: $1,769 · 2023: $743 · 2024: $124 · 2025: $76.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.43 | 2021-2022 | |
| Novo Nordisk INC | $364.57 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.60 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $319.71 | 2021-2023 | Breztri |
| Pfizer INC. | $236.78 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $191.56 | 2021-2023 | |
| Abbott Laboratories | $190.17 | 2021-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $187.51 | 2021-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $183.56 | 2021-2022 | |
| Glaxosmithkline, LLC. | $162.29 | 2021-2022 | |
| Esperion Therapeutics, INC. | $155.95 | 2021-2023 | Nexletol |
| Amgen INC. | $153.60 | 2021-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $153.46 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $137.58 | 2021-2023 | |
| Scpharmaceuticals INC. | $121.48 | 2024-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.